Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?

Dekker I, Sombekke MH, Balk LJ, Moraal B, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2019 Aug 2:1352458519864933. doi: 10.1177/1352458519864933. [Epub ahead of print]

PMID:
31373535
2.

Single-subject structural cortical networks in clinically isolated syndrome.

Collorone S, Prados F, Hagens MH, Tur C, Kanber B, Sudre CH, Lukas C, Gasperini C, Oreja-Guevara C, Andelova M, Ciccarelli O, Wattjes MP, Ourselin S, Altmann DR, Tijms BM, Barkhof F, Toosy AT; MAGNIMS Study Group.

Mult Scler. 2019 Jul 24:1352458519865739. doi: 10.1177/1352458519865739. [Epub ahead of print]

3.

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines.

Filippi M, Preziosa P, Banwell BL, Barkhof F, Ciccarelli O, De Stefano N, Geurts JJG, Paul F, Reich DS, Toosy AT, Traboulsee A, Wattjes MP, Yousry TA, Gass A, Lubetzki C, Weinshenker BG, Rocca MA.

Brain. 2019 Jun 17. pii: awz144. doi: 10.1093/brain/awz144. [Epub ahead of print]

4.

Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.

Loonstra FC, Verberk IMW, Wijburg MT, Wattjes MP, Teunissen CE, van Oosten BW, Uitdehaag BMJ, Killestein J, van Kempen ZLE.

Ann Neurol. 2019 Aug;86(2):322-324. doi: 10.1002/ana.25523. Epub 2019 Jun 26. No abstract available.

PMID:
31192473
5.

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.

Dekker I, Leurs CE, Hagens MHJ, van Kempen ZLE, Kleerekooper I, Lissenberg-Witte BI, Barkhof F, Uitdehaag BMJ, Balk LJ, Wattjes MP, Killestein J.

Mult Scler Relat Disord. 2019 Aug;33:82-87. doi: 10.1016/j.msard.2019.05.017. Epub 2019 May 28.

PMID:
31174043
6.

Towards a standard MRI protocol for multiple sclerosis across the UK.

Schmierer K, Campion T, Sinclair A, van Hecke W, Matthews PM, Wattjes MP.

Br J Radiol. 2019 May 14:20180926. doi: 10.1259/bjr.20180926. [Epub ahead of print]

PMID:
30994035
7.

Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project.

van Maurik IS, Slot RER, Verfaillie SCJ, Zwan MD, Bouwman FH, Prins ND, Teunissen CE, Scheltens P, Barkhof F, Wattjes MP, Molinuevo JL, Rami L, Wolfsgruber S, Peters O, Jessen F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Res Ther. 2019 Apr 16;11(1):33. doi: 10.1186/s13195-019-0487-y.

8.

Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis.

Schwenkenbecher P, Wurster U, Konen FF, Gingele S, Sühs KW, Wattjes MP, Stangel M, Skripuletz T.

Front Neurol. 2019 Mar 15;10:188. doi: 10.3389/fneur.2019.00188. eCollection 2019. Review.

9.

Individual Prediction of Behavioral Variant Frontotemporal Dementia Development Using Multivariate Pattern Analysis of Magnetic Resonance Imaging Data.

Zhutovsky P, Vijverberg EGB, Bruin WB, Thomas RM, Wattjes MP, Pijnenburg YAL, van Wingen GA, Dols A.

J Alzheimers Dis. 2019;68(3):1229-1241. doi: 10.3233/JAD-181004.

PMID:
30909224
10.

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ.

CNS Neurosci Ther. 2019 Jun;25(6):697-703. doi: 10.1111/cns.13096. Epub 2019 Feb 12.

11.

The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls-A longitudinal study.

Emanuel AL, van Duinkerken E, Wattjes MP, Klein M, Barkhof F, Snoek FJ, Diamant M, Eringa EC, IJzerman RG, Serné EH.

Microcirculation. 2019 Apr;26(3):e12530. doi: 10.1111/micc.12530. Epub 2019 Feb 22.

12.

Exploring resting state connectivity in patients with psychotic depression.

Oudega ML, van der Werf YD, Dols A, Wattjes MP, Barkhof F, Bouckaert F, Vandenbulcke M, De Winter FL, Sienaert P, Eikelenboom P, Stek ML, van den Heuvel OA, Emsell L, Rhebergen D, van Exel E.

PLoS One. 2019 Jan 17;14(1):e0209908. doi: 10.1371/journal.pone.0209908. eCollection 2019.

13.

Predicting clinical progression in multiple sclerosis after 6 and 12 years.

Dekker I, Eijlers AJC, Popescu V, Balk LJ, Vrenken H, Wattjes MP, Uitdehaag BMJ, Killestein J, Geurts JJG, Barkhof F, Schoonheim MM.

Eur J Neurol. 2019 Jun;26(6):893-902. doi: 10.1111/ene.13904. Epub 2019 Feb 2.

14.

Venoplasty in MS: Therapeutic intervention without any evidence.

Paul F, Wattjes MP.

Neurology. 2018 Oct 30;91(18):815-816. doi: 10.1212/WNL.0000000000006419. Epub 2018 Sep 28. No abstract available.

PMID:
30266888
15.

Imaging of meningeal inflammation should become part of the routine MRI protocol - No.

Wattjes MP, Killestein J.

Mult Scler. 2019 Mar;25(3):331-333. doi: 10.1177/1352458518799642. Epub 2018 Sep 4. No abstract available.

PMID:
30179073
16.

Gray matter atrophy in dementia with Lewy bodies with and without concomitant Alzheimer's disease pathology.

van der Zande JJ, Steenwijk MD, Ten Kate M, Wattjes MP, Scheltens P, Lemstra AW.

Neurobiol Aging. 2018 Nov;71:171-178. doi: 10.1016/j.neurobiolaging.2018.07.005. Epub 2018 Jul 17.

PMID:
30149288
17.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):44-46. doi: 10.1136/jnnp-2018-318261. Epub 2018 Aug 12.

PMID:
30100552
18.

Intracerebral lymphoproliferative disorder in an MS patient treated with fingolimod.

de Jong BA, van Kempen ZLE, Wattjes MP, Smit PM, Peferoen L, Berry D, Chamuleau MED, de Jong D.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 10;5(5):e483. doi: 10.1212/NXI.0000000000000483. eCollection 2018 Sep. No abstract available.

19.

Three-Tesla MRI does not improve the diagnosis of multiple sclerosis: A multicenter study.

Hagens MHJ, Burggraaff J, Kilsdonk ID, de Vos ML, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Ciccarelli O, Gasperini C, Lukas C, Wattjes MP, Barkhof F; MAGNIMS Study Group.

Neurology. 2018 Jul 17;91(3):e249-e257. doi: 10.1212/WNL.0000000000005825. Epub 2018 Jun 20.

20.

[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Aktas O, Wattjes MP, Stangel M, Hartung HP.

Nervenarzt. 2018 Dec;89(12):1344-1354. doi: 10.1007/s00115-018-0550-0. Review. German.

PMID:
29876600
21.

The course of apathy in late-life depression treated with electroconvulsive therapy; a prospective cohort study.

Carlier A, van Exel E, Dols A, Bouckaert F, Sienaert P, Ten Kate M, Wattjes MP, Vandenbulcke M, Stek ML, Rhebergen D.

Int J Geriatr Psychiatry. 2018 May 30. doi: 10.1002/gps.4917. [Epub ahead of print]

PMID:
29851173
22.

Imaging Patterns of Muscle Atrophy.

Weber MA, Wolf M, Wattjes MP.

Semin Musculoskelet Radiol. 2018 Jul;22(3):299-306. doi: 10.1055/s-0038-1641574. Epub 2018 May 23. Review.

PMID:
29791958
23.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

24.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

25.

Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study.

Hagens MH, Burggraaff J, Kilsdonk ID, Ruggieri S, Collorone S, Cortese R, Cawley N, Sbardella E, Andelova M, Amann M, Lieb JM, Pantano P, Lissenberg-Witte BI, Killestein J, Oreja-Guevara C, Wuerfel J, Ciccarelli O, Gasperini C, Lukas C, Rovira A, Barkhof F, Wattjes MP; MAGNIMS Study Group.

Mult Scler. 2019 Mar;25(3):352-360. doi: 10.1177/1352458517751647. Epub 2018 Jan 12.

26.

Gray matter networks and cognitive impairment in multiple sclerosis.

Rimkus CM, Schoonheim MM, Steenwijk MD, Vrenken H, Eijlers AJ, Killestein J, Wattjes MP, Leite CC, Barkhof F, Tijms BM.

Mult Scler. 2019 Mar;25(3):382-391. doi: 10.1177/1352458517751650. Epub 2018 Jan 11.

27.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
28.

Fulminant intramedullary spinal cord sarcoidosis.

Graf J, Ringelstein M, Aktas O, Wattjes MP, Hartung HP.

Mult Scler Relat Disord. 2017 Nov;18:47-48. doi: 10.1016/j.msard.2017.09.010. Epub 2017 Sep 13.

PMID:
29141820
29.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6. Erratum in: Mult Scler. 2019 Jan;25(1):NP2.

30.

Neuromyelitis optica spectrum disorder mimicking multiple sclerosis.

van Rooij LC, Wattjes MP, de Jong BA, van Oosten BW.

Mult Scler Relat Disord. 2017 Oct;17:54-56. doi: 10.1016/j.msard.2017.06.009. Epub 2017 Jun 29.

PMID:
29055475
31.

Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project.

van Maurik IS, Zwan MD, Tijms BM, Bouwman FH, Teunissen CE, Scheltens P, Wattjes MP, Barkhof F, Berkhof J, van der Flier WM; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Neurol. 2017 Dec 1;74(12):1481-1491. doi: 10.1001/jamaneurol.2017.2712.

32.

[Imaging of primary muscular diseases : What do neurologists expect from radiologists?]

Wattjes MP, Fischmann A, Fischer D.

Radiologe. 2017 Dec;57(12):1005-1011. doi: 10.1007/s00117-017-0309-9. Review. German.

PMID:
28986620
33.

The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study.

Martens RM, Bechten A, Ingala S, van Schijndel RA, Machado VB, de Jong MC, Sanchez E, Purcell D, Arrighi MH, Brashear RH, Wattjes MP, Barkhof F.

Eur Radiol. 2018 Mar;28(3):1215-1226. doi: 10.1007/s00330-017-5022-6. Epub 2017 Sep 27.

34.

Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.

de Sitter A, Steenwijk MD, Ruet A, Versteeg A, Liu Y, van Schijndel RA, Pouwels PJW, Kilsdonk ID, Cover KS, van Dijk BW, Ropele S, Rocca MA, Yiannakas M, Wattjes MP, Damangir S, Frisoni GB, Sastre-Garriga J, Rovira A, Enzinger C, Filippi M, Frederiksen J, Ciccarelli O, Kappos L, Barkhof F, Vrenken H; MAGNIMS study group and for neuGRID.

Neuroimage. 2017 Dec;163:106-114. doi: 10.1016/j.neuroimage.2017.09.011. Epub 2017 Sep 9.

PMID:
28899746
35.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2018 Oct;24(11):1453-1460. doi: 10.1177/1352458517726381. Epub 2017 Aug 21.

36.

Erratum to: Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Aug;264(8):1833-1836. doi: 10.1007/s00415-017-8557-1. No abstract available.

PMID:
28711999
37.

John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.

van Kempen ZLE, Leurs CE, de Vries A, Vennegoor A, Rispens T, Wattjes MP, Killestein J.

Eur J Neurol. 2017 Sep;24(9):1196-1199. doi: 10.1111/ene.13355. Epub 2017 Jul 14.

PMID:
28707781
38.

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.

Gieselbach RJ, Muller-Hansma AH, Wijburg MT, de Bruin-Weller MS, van Oosten BW, Nieuwkamp DJ, Coenjaerts FE, Wattjes MP, Murk JL.

J Neurol. 2017 Jun;264(6):1155-1164. doi: 10.1007/s00415-017-8509-9. Epub 2017 May 23. Review. Erratum in: J Neurol. 2017 Jul 15;:.

PMID:
28536921
39.

MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis.

Rhodius-Meester HFM, Benedictus MR, Wattjes MP, Barkhof F, Scheltens P, Muller M, van der Flier WM.

Front Aging Neurosci. 2017 May 9;9:117. doi: 10.3389/fnagi.2017.00117. eCollection 2017.

40.

Application of the CSF JCV antibody index to early natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C, Wijburg MT, Hartung HP, Killestein J, Adams O, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1092-1094. doi: 10.1136/jnnp-2016-315298. Epub 2017 May 10. No abstract available.

PMID:
28490505
41.

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.

van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J.

Mult Scler. 2018 May;24(6):805-810. doi: 10.1177/1352458517708464. Epub 2017 May 9.

42.

In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?

Kilsdonk ID, Schoonheim M, Wattjes MP.

Mult Scler. 2017 Jul;23(8):1169-1171. doi: 10.1177/1352458517704924. Epub 2017 Apr 18. No abstract available.

43.

Brain and Spinal Cord MR Imaging Features in Multiple Sclerosis and Variants.

Dekker I, Wattjes MP.

Neuroimaging Clin N Am. 2017 May;27(2):205-227. doi: 10.1016/j.nic.2016.12.002. Review.

PMID:
28391782
44.

Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N.

Br J Radiol. 2017 Jun;90(1074):20160721. doi: 10.1259/bjr.20160721. Epub 2017 Apr 26. Review.

45.

Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis.

Meijer WJ, Linn FH, Wensing AM, Leavis HL, van Riel D, GeurtsvanKessel CH, Wattjes MP, Murk JL.

JMM Case Rep. 2016 Dec 19;3(6):e005076. doi: 10.1099/jmmcr.0.005076. eCollection 2016 Dec.

46.

Progressive multifocal leukoencephalopathy and black fungus in a patient with rheumatoid arthritis without severe lymphocytopenia.

de Regt MJ, Murk JL, Schneider-Hohendorf T, Wattjes MP, Hoepelman AI, Arends JE.

JMM Case Rep. 2016 Aug 30;3(4):e005053. doi: 10.1099/jmmcr.0.005053. eCollection 2016 Aug.

47.

High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - Commentary.

Wattjes MP, Warnke C.

Mult Scler. 2017 May;23(6):770-771. doi: 10.1177/1352458516685170. Epub 2017 Mar 1. No abstract available.

PMID:
28287040
48.

Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design.

de Wilde A, van Maurik IS, Kunneman M, Bouwman F, Zwan M, Willemse EA, Biessels GJ, Minkman M, Pel R, Schoonenboom NS, Smets EM, Wattjes MP, Barkhof F, Stephens A, van Lier EJ, Batrla-Utermann R, Scheltens P, Teunissen CE, van Berckel BN, van der Flier WM.

Alzheimers Dement (Amst). 2017 Jan 23;6:143-151. doi: 10.1016/j.dadm.2017.01.003. eCollection 2017.

49.

Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.

van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023. Epub 2016 Dec 13.

PMID:
28112019
50.

Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities.

Bechten A, Wattjes MP, Purcell DD, Aliaga ES, Daams M, Brashear HR, Arrighi HM, Barkhof F.

J Neuroimaging. 2017 May;27(3):318-325. doi: 10.1111/jon.12422. Epub 2017 Jan 19.

PMID:
28102639

Supplemental Content

Loading ...
Support Center